# The association between age and high-intensity treatment in traumatic brain injury patients: a CENTER-TBI study

Ernest van Veen<sup>1,2</sup>, Erwin J. O. Kompanje<sup>2,3</sup>, Mathieu van der Jagt<sup>2</sup>, Ana Mikolić<sup>1</sup>, Giuseppe Citerio<sup>4,5</sup>, Nino Stocchetti<sup>6,7</sup>, Diederik Gommers<sup>1</sup>, David K. Menon<sup>8</sup>, Andrew I. R. Maas<sup>9</sup>, Hester F. Lingsma<sup>2</sup> and the CENTER-TBI investigators and participants\*

<sup>1</sup> Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.

<sup>2</sup> Department of Intensive Care Adults, Erasmus MC - University Medical Center, Rotterdam, the Netherlands.

<sup>3</sup> Department of Medical Ethics and Philosophy of Medicine, Erasmus University Medical Center,

Rotterdam, the Netherlands.

<sup>4</sup> School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy.

<sup>5</sup> Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.

<sup>6</sup> Department of Physiopathology and Transplantation, Milan University, Milan, Italy.

<sup>7</sup> Neuro ICU Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.

<sup>8</sup> Department of Anaesthesia, University of Cambridge, Cambridge, United Kingdom.

<sup>9</sup> Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem,

Belgium.

\* Listed at the end of the manuscript.

1

# ABSTRACT

**Introduction:** Older age is associated with worse outcome after traumatic brain injury (TBI). Whether this association is entirely driven by frailty, or clinicians' reluctance to give specific treatments to older patients is unclear. Therefore, we aimed to confirm the association between age and worse outcome, and to assess the association between age and received high-intensity treatment (HIT).

**Methods:** We included TBI patients aged 16 and older from the CENTER-TBI study. The association between age and HIT, and between age and outcome (the Glasgow Outcome Scale Extended (GOSE) at 6 months), was analyzed using multivariable ordinal and logistic regression respectively. In the overall cohort, HIT was defined as receiving emergency intracranial surgery, or ICU admission. In the subset of patients admitted to the ICU, HIT was defined as receiving metabolic suppression, intensive hypocapnia, hypothermia below 35 °C, decompressive craniectomy, or intracranial surgery not scheduled on admission. We adjusted for pre-injury health, injury severity (Glasgow Coma Scale (GCS) motor score and pupillary reactivity at baseline; major extracranial injury (MEI); Marshall CT classification), and in the subset of ICU patients for the median ICP before receiving any HIT.

**Results:** In total, 4349 patients were included. Of these, 1999 patients (46%) were admitted to the ICU. The median age was 51 years. Every ten-year increase in age for patients over 65, was associated with worse outcome (OR = 0.6, CI = 0.5 - 0.7, OR in the subset of ICU patients = 0.5, CI = 0.3 - 0.5). Furthermore, every ten-year increase in age for patients over 65 was associated with a lower likelihood of receiving emergency intracranial surgery (OR = 0.4, CI = 0.3 - 0.6), and ICU admission (OR = 0.6, CI = 0.5 - 0.8). Similarly, in the subset of ICU patients, every ten-year increase in age for patients over 65, was associated with a lower likelihood of receiving neuromuscular blockade (OR = 0.6, CI = 0.4 - 0.9), intensive hypocapnia (OR = 0.2, CI = 0.1 - 0.9), decompressive craniectomy (OR = 0.4, CI = 0.2 - 0.8), and intracranial surgery (OR = 0.5, CI = 0.3 - 0.8).

**Conclusion:** Older patients have poorer outcome, and were less likely to receive high-intensity treatments, independent of patient and injury characteristics. Clinicians should not withhold high-intensity treatments solely based on older age. Educating clinicians about this delicate topic, and performing further comparative effectiveness research focusing on older patients may improve diagnosis, treatments, and understanding of TBI outcomes in this group.

Keywords: Traumatic brain injury, critical care, intensive care units, elderly

# **INTRODUCTION**

Traumatic brain injury (TBI) is a serious societal problem and a tremendous burden for patients and their families (1). In recent decades, TBI occurrence shifted towards the older age groups ( $\geq 65$  years) (2), presenting with a low-energy fall (2). This shift in TBI epidemiology is relevant since older age is associated with worse outcomes after TBI (3-9).

Despite this shift, older adults with TBI are often excluded from research (10), even though scientific evidence is important for the creation of guidelines. Without these guidelines, clinicians have to balance risks and benefits of treatments individually. This may in turn lead to differences in outcome (11), as is warned for in, among other disciplines, older adults with cancer (12), and rheumatoid arthritis (13).

Examples of differences in management between older and younger adults with TBI, are the influence of age on the decision to perform neurosurgical procedures (14), or to implement highintensity treatment (HIT) (15, 16). Limitations of these studies include the sample size, and lack of adjustment for intracranial pressure (ICP). Pessimistic assumptions (based on these limitations) could increase the risk of a self-fulfilling prophecy, negatively impacting (long-term) outcomes for older adults (15).

To add to the scarce literature on older adults with TBI, we aimed to confirm the association between increasing age and worse outcome, and to assess the association between age and received HIT.

### **METHODS**

### **Study population**

The Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI, registered at clinicaltrials.gov NCT02210221) is a prospective cohort study conducted in 63 centers from 18 countries across Europe and Israel between 2014 and 2017. Patients were included if they arrived at the hospital within 24 hours after injury with a clinical diagnosis of TBI, and if patients had an indication for a head computed tomography (CT) scan. Patients with a severe preexisting neurological disorder that would confound outcome assessment, were excluded. For each center ethics approval was acquired and consent for participation was obtained from all patients or their proxies. The general methods and aims of the CENTER-TBI study were previously described (17, 18).

For this study, we included all patients aged 16 or older. We also specifically studied the subgroup of patients admitted to the ICU. We extracted data on demographics, (pre)injury, admission, imaging, monitoring, treatment, and outcome characteristics.

# Treatments

We selected treatment variables based on clinical considerations. These treatment variables were described in the e-CRF exactly as written below, and were scored (if applicable) once daily. In the entire cohort (patients admitted to the ER, ward, or ICU), high-intensity treatment (HIT) was defined as one or more of the following treatments:

- ICU admission (yes/no).
- Emergency intracranial operation (having received a craniotomy, decompressive craniectomy, depressed skull fracture or other intracranial procedures) (yes/no).

In patients admitted to the ICU, HIT was defined as having received at least one of the following treatments:

- Metabolic suppression for ICP control with high dose barbiturates or propofol during the ICU stay (yes/no).
- Neuromuscular blockade (paralysis) during ICU stay (yes/no).
- Intensive hypocapnia [PaCO2 < 4.0 kPa (30 mmHg)] during ICU stay (yes/no).

- Hypothermic treatment (only treatment, not accidental temperatures) below 35°C during ICU stay (yes/no).
- Decompressive craniectomy (yes/no).
- Intracranial operation for progressive mass lesion, not scheduled on admission (yes/no).

# Outcomes

We used the Glasgow Outcome Scale-Extended (GOSE) as the outcome measure (19). GOSE is an eight-point outcome scale that was measured six months after injury: (1) dead; (2) vegetative state; (3) lower severe disability; (4) upper severe disability; (5) lower moderate disability; (6) upper moderate disability; (7) lower good recovery; and (8) upper good recovery. Categories 2 and 3 were combined, resulting in a seven-point ordinal scale.

### Statistical analyses

### Descriptive statistics

Baseline characteristics were presented as median values with interquartile ranges (IQRs) for continuous variables and as frequencies and percentages for categorical variables. We compared characteristics between age groups (i.e. age 65 or over vs. age 65 or under) for the entire and ICU cohort. We used the Pearson  $\chi^2$  test for categorical variables and the independent t-test or Mann–Whitney U-Test for continuous variables to test for differences between these groups.

### Baseline variables

We collapsed categories 3 and 4 of the American Society of Anesthesiologists (ASA) Physical Status classification because category 4 had <10 patients. Second, we collapsed categories V and VI of the Marshall CT classification as grading V and VI could not be differentiated on central review as the raters were unaware of (intent to) surgery. Last, to compare groups at baseline we calculated the expected probability of mortality and unfavorable outcome using the International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT) core model (8).

### Regression

We used ordinal and logistic regression, with GOSE and treatments as dependent variables to assess:

- 1. To confirm if older age is associated with worse outcome (GOSE) (3-9).
- 2. To assess if older age is associated with a lower probability to receive HIT (15).

All models were adjusted for age; sex; cause of injury (road traffic accident, fall, or other); American Society of Anesthesiologists Physical Status (ASAPS) classification (healthy patient, patients with mild systemic disease, patients with severe systemic disease); pre-injury use of anticoagulants or platelet inhibitors; pre-injury use of beta-blockers; GCS motor score at baseline; pupillary reactivity at baseline; major extracranial injury (MEI); Marshall CT classification. Models for the subset of patients admitted to the ICU, were additionally adjusted for the median ICP scores measured before a patient received any HIT in the ICU.

We analyzed age as a continuous variable and allowed for non-linear effects by estimating different effects for patients over and under 65. As a sensitivity analysis we estimated different effects for patients over and under 50, based on several important longitudinal studies of aging, and a recent systematic review on geriatric patients with TBI (3, 20, 21). Furthermore, as a sensitivity analysis, based on clinical judgment, we estimated different effects for patients over and under 80.

Associations between age and GOSE were expressed as Odds Ratios (ORs) with 95% confidence intervals (CIs). The ordinal logistic regression estimates a common OR for overall health state transitions within the GOSE.

All statistical analyses were performed in R studio (22). Multiple imputation was used to handle missing values, using the mice package in R (23). Data were accessed using 'Neurobot' (<u>http://neurobot.incf.org;</u> RRID: SCR\_01700), vs 3.0 (data freeze: October 2021).

# RESULTS

#### *Characteristics study cohort – (Table 1-2)*

The entire study cohort consisted of 4349 patients. The median age was 51 years old (IQR 32-67), and the main cause of injury was an incidental fall (1955, 46%) (Table 1). The ICU cohort consisted of 1999 patients. The median age was 51 years old (IQR 31-66), and the main cause of injury was a road traffic accident (887, 45%) (Table 2).

### *Baseline characteristics* $\leq$ 65 years versus >65 years – entire cohort (Table 1)

Of the 4349 patients, 1139 (26.2%) were >65 years old. Patients >65 were less often male (58.7% versus 70.5%), and the most prevalent cause of injury in patients >65 was a fall (69.3%), whereas it was a road traffic incident in patients  $\leq$ 65 (44.2%). Patients >65 more often had a mild or severe systemic disease pre-injury (79.8% versus 30.7%), and more often used medication such as anticoagulants or platelet inhibitors (49% versus 6%), and beta-blockers (28.1% versus 4.1%). Patients >65 more often had a GCS motor score of 6 (70% versus 66.8%), more often had a Marshall CT classification of V or VI (30.6% versus 17.6%), but less often had MEI (29.6% versus 37.4%). Patients >65 and  $\leq$ 65 had a similar length of hospital stay of generally 5 days. Six months after their hospital stay, patients >65 were more often deceased than younger patients (26.4% versus 7.6% respectively) (Table 1).

### Table 1. Baseline characteristics entire cohort

#### *Baseline characteristics* $\leq$ 65 *years versus* > 65 *years* – *ICU cohort* (*Table 2*)

Of the 1999 patients, 513 (25.7%) were >65 years old. Patients >65 were less often male (66.1% versus 76.2%), and the most prevalent cause of injury in patients >65 was a fall (58.9%), whereas it was a road traffic incident in patients  $\leq$ 65 (49.7%). Patients >65 more often had a mild or severe systemic disease pre-injury (78.7% versus 31.3%), and more often used medication such as anticoagulants or platelet inhibitors (48.5 % versus 5.6%), and beta-blockers (28.7% versus 4.4%). Patients >65 less often had a GCS motor score of 1 (29.5% versus 49.7%), but more often had a

Marshall CT classification of V or VI (56.6% versus 32.6%). MEI was less prevalent in patients >65 (46.8% versus 57.6%). Patients >65 were less often intubated (73.5% versus 79.0%), and less often had an ICP monitor during their ICU stay (35.3% versus 47.4%), with a median ICP before receiving any ICP lowering therapies of 11.12 mmHg compared to 11.78 mmHg in patients  $\leq$ 65. Patients >65 generally had a shorter length of hospital stay of 12 days compared to 16 days for their younger counterparts. Six months after their hospital stay, patients >65 were more often deceased than patients  $\leq$ 65 (44.1% versus 14.3% respectively) (Table 2).

# Table 2. Baseline characteristics ICU cohort

### Association of age with GOSE (Table 3-5, Figure 1-3)

Increasing age was independently associated with worse GOSE for patients in the entire cohort (OR per 10 years if over 65 = 0.62, CI = 0.54 - 0.70) and in the ICU cohort (OR per 10 years if over 65 = 0.48, CI = 0.33 - 0.52) (Table 3, Figure 1-3). This was also the case for patients under 65 in the entire cohort (OR per 10 years = 0.90, CI = 0.84 - 0.91), and in the ICU cohort (OR per 10 years = 0.84, CI = 0.80 - 0.91) (Table 3). Comparable associations were found in the sensitivity analyses.

### Entire cohort (Table 3-5, Figure 1)

After the age of 65, increasing age was independently associated with a lower probability of receiving emergency intracranial surgery (OR per 10 years = 0.43, CI = 0.32 - 0.56) (Table 3, Figure 1). Further, increasing age was associated with a lower probability of being admitted to the ICU (OR per 10 years if over 65 = 0.63, CI = 0.52 - 0.78) (Table 3, Figure 1). Similar results, were found for patients under the age of 65, for emergency intracranial surgery (OR per 10 years = 0.98, CI = 0.89 - 1.07), and ICU admission (OR per 10 years = 0.94, CI = 0.87 - 1.01) (Table 3). In the sensitivity analyses, comparable results were found (Table 4-5).

ICU cohort (Table 3-5, Figure 2-3)

For patients over 65, an increase in age was independently associated with a lower probability of receiving neuromuscular blockade (OR per 10 years = 0.60, CI = 0.41 - 0.90), a lower likelihood of receiving intensive hypocapnia (OR per 10 years if over 65 = 0.22, CI = 0.06 - 0.86), a lower likelihood of decompressive craniectomy (OR per 10 years = 0.43, CI = 0.24 - 0.75), and a lower probability for intracranial surgery (OR per 10 years = 0.51, CI = 0.30 - 0.84). When older than 65, increasing age was not associated with a lower probability of receiving metabolic suppression with high dose barbiturates or propofol (OR per 10 years = 0.90, CI = 0.63 - 1.38), and the likelihood of receiving hypothermic therapy below  $35^{\circ}$ C (OR per 10 years = 1.27, CI = 0.63 - 1.38) (Table 3, and Figure 1-3). Similar results were found in the sensitivity analyses (Table 4-5).

 Table 3. Effect of age on outcome and on the probability of receiving one or more high intensity

 treatments

 Table 4. Sensitivity analyses - Effect of age on outcome and on the probability of receiving one

 or more high intensity treatments

 Table 5. Sensitivity analyses - Effect of age on outcome and on the probability of receiving one

 or more high intensity treatments

Figure 1. Predicted probabilities of unfavorable outcome, ICU admission and emergency intracranial surgery

Figure 2. Predicted probabilities of unfavorable outcome, metabolic suppression, neuromuscular blockage and hypothermia

Figure 3. Predicted probabilities of unfavorable outcome, intensive hyperventilation, decompressive craniectomy and intracranial surgery

The graphs show the probability of receiving a certain therapy with increasing age in a patient who did not use anticoagulants or platelet inhibitors, or betablockers, who had a mild systemic disease, whose cause of injury was a fall, after which the GCS motor score was 2, the pupils were both reactive, there were no MEI, and a Marshall CT score of II.

# DISCUSSION

We aimed to confirm the association between age and worse outcome, and to assess the association between age and received high-intensity treatment (HIT). Increasing age is independently associated with a worse outcome, and a lower probability to receive HIT, such as emergency intracranial surgery, ICU admission, and ICP lowering therapies (e.g. intensive hypocapnia, and decompressive craniectomy).

With this new body of evidence, it is important to elucidate that invalid pessimistic assumptions are not the only possible explanation of worse outcome in older patients with TBI. Important factors that may prevent high-intensity treatment for older adults with TBI, include the (previous) wish to withhold treatment of the patient or surrogate, and a higher expected probability of a bad outcome in the opinion of the clinician, patient, or surrogate, based on clinical experience. Furthermore, even though more intensive treatment has been shown to be effective in some older patients with TBI (24-26), pre-existent comorbidities and age are still major drivers of outcome. Focusing on frailty instead of on biological age, may therefore be more relevant. A newly developed, and validated frailty index for patients with TBI, is the CENTER-TBI frailty index score (27). A higher CENTER-TBI frailty index score significantly increases the risk of unfavorable outcome, regardless of age. Clinicians should therefore be reluctant to let age alone drive the decision to apply less intensive treatment, indicating ageism. Ageism can be defined as age-related discrimination (28), and plays a role in all layers of (Western) society (29). The influence of ageism in the hospital setting became more apparent during the covid-19 pandemic (30). Ageism negatively impacts the probability of a positive outcome for older patients (31), potentially fueling a self-fulfilling prophecy.

Multiple previous studies indicate the possible existence of a self-fulfilling prophecy. Skaansar et al. (15) recently warned for the possibility of a self-fulfilling prophecy after finding that treatment intensity decreased with advanced age, and that a decrease in treatment intensity was associated with an increased risk of mortality, concluding that mortality may be lower if HIT would be given to older patients (15). Kirkman et al. (32) found that it took longer for older patients to obtain an initial head CT, that the chances of being transferred to a neurotrauma center were lower, and that the CT was less likely to be reviewed by a senior physician (32). Some centers have suggested age-dependent

limitations for more intensive treatments (33-35). Other centers tend to be more liberal and are inclined to admit all older adults after TBI to the ICU for neurological assessments and head CTs (36). Moreover, in the majority of centers in Europe, age played a role in the decision to withdraw LSM (37), and the decision to perform neurosurgical procedures (14). A recent study, however, showed that age was not associated with faster withdrawal of LSM (38). Future research should elucidate if a self-fulfilling prophecy, induced by ageism may be a relevant cause of higher mortality in older patients with TBI. A randomized controlled trial on this topic may be ethically challenging. Therefore, another option is comparative effectiveness research between hospitals, or countries with different treatment regimes. One such option may be a comparison between Chinese centers and European centers, since a provider profiling between different neurotrauma centers suggested that China less often applies restrictions in therapies based on age (39).

We found differences between baseline characteristics in patients over 65 and younger patients. In line with previous literature (40), the GCS motor score on admission generally seemed to be more favorable in patients over 65. Two important explanations may play a role here. One explanation may be the cause of injury. As seen in our study, and also in the study of Lecky et al. (41) on the CENTER-TBI registry, elderly patients more often have a low-energy fall compared with younger patients. Another explanation pertains to atrophy of the brain associated with ageing. Due to this natural process, older patients may have higher intracranial compliance in case of minor or moderate space occupying traumatic lesions, and, consequently, less often need high-intensity treatments to manage ICP. However, given the statistical adjustment for pupillary reactivity and Marshall CT score, we think this possible confounding factor of brain atrophy with higher age should not be relevant for our analyses.

Furthermore, we found that patients older than 65 years more often used beta-blockers, anticoagulants, or platelet inhibitors. Beta-blockers may improve outcomes after TBI in adults (42). The use of anticoagulants is associated with worse initial TBI severity (43-46) and some studies have reported worse outcomes and higher need for neurosurgical intervention (43, 44, 47-49). Moreover, we found more CT abnormalities for older patients, in line with previous literature (50, 51). The higher prevalence in older patients may result from various factors, ranging from biological factors

such as vessels being more vulnerable to rupture, more atrophy (leaving more space for blood within the skull), and the higher use of anticoagulants (52-54).

The CENTER-TBI study is unique for its extensive data collection in multiple centers, enrolling TBI patients with varying injury severity across a wide range of European centers. Furthermore, the observational design of the CENTER-TBI study, ensures larger generalizability of the results compared to a clinical trial with strict enrollment criteria (55). There are also limitations that should be considered when interpreting the results. First, all centers in the CENTER-TBI study are committed to TBI research. This might limit generalizability since it is only a sample of the neurotrauma centers in Europe. Second, HIT was based on clinical considerations that could have differed in a different setting (other country, other clinicians). We included a variety of high-intensity treatments, but cannot guarantee that we included all relevant treatments. However, given the consistency of our results across all therapies in different cohorts, including sensitivity analyses, we expect results to be similar for other treatments. Third, we may not have controlled for all relevant factors that could have influenced the outcome or the treatment decision. Fourth, for statistical reasons, it would have been preferable to have included more patients, especially older patients. Last, there was some missing data. However, to lower the impact of missing data we multiply imputed missing data of variables that were included in our models.

# CONCLUSION

Older patients have poorer outcome, and were less likely to receive high-intensity treatments, independent of patient and injury characteristics. Clinicians should not withhold high-intensity treatments solely based on older age. Educating clinicians about this delicate topic, and performing further comparative effectiveness research focusing on older patients may improve diagnosis, treatments, and understanding of TBI outcomes in this group.

# DECLARATIONS

#### Ethics approval and consent to participate

The Medical Ethics Committees of all participating centers approved the CENTER-TBI study, and informed consent was obtained according to local regulations

### Availability of data and materials

The data supporting the findings in the study are available upon reasonable request from the corresponding Author (EvV) and are stored at <u>https://center-tbi.incf.org/</u>

### Conflicts of Interest

GC is the Editor-in-Chief of Intensive Care Medicine. GC reports grants, and personal fees as a Speakers' Bureau Member and Advisory Board Member from Integra and Neuroptics, all outside the submitted work. DKM reports grants from the European Union and UK National Institute for Health Research, during the conduct of the study; grants, personal fees, and non-financial support from GlaxoSmithKline; personal fees from Neurotrauma Sciences, Lantmaanen AB, Pressura, and Pfizer, outside of the submitted work. AIRM reports grants from the European Union (Fp7: 602150), during the conduct of the study and personal fees from Integra LifeSciences, Neurotrauma Sciences, Novartis, and PressuraNeuro, outside of the submitted work. The other authors declare that they have no competing interests.

### Funding

Data used in preparation of this manuscript were obtained in the context of CENTER-TBI, a large collaborative project, supported by the Framework 7 program of the European Union (602150). The funder had no role in the design of the study, the collection, analysis, and interpretation of data, or in writing the manuscript.

David K. Menon was supported by a Senior Investigator Award from the National Institute for Health Research (UK). The funder had no role in the design of the study, the collection, analysis, and interpretation of data, or in writing the manuscript.

#### Authors' contributions

EvV analyzed the data and drafted the manuscript, and the supplementary tables and figures. All coauthors gave feedback on the manuscript. HL supervised the project. All coauthors gave feedback on (and approved) the final version of the manuscript.

# **CENTER-TBI INVESTIGATORS AND PARTICIPANTS**

Cecilia Åkerlund1, Krisztina Amrein2, Nada Andelic3, Lasse Andreassen4, Audny Anke5, Anna Antoni6, Gérard Audibert7, Philippe Azouvi8, Maria Luisa Azzolini9, Ronald Bartels10, Pál Barzó11, Romuald Beauvais12, Ronny Beer13, Bo-Michael Bellander14, Antonio Belli15, Habib Benali16, Maurizio Berardino17, Luigi Beretta9, Morten Blaabjerg18, Peter Bragge19, Alexandra Brazinova20, Vibeke Brinck21, Joanne Brooker22, Camilla Brorsson23, Andras Buki24, Monika Bullinger25, Manuel Cabeleira26, Alessio Caccioppola27, Emiliana Calappi 27, Maria Rosa Calvi9, Peter Cameron28, Guillermo Carbayo Lozano29, Marco Carbonara27, Simona Cavallo17, Giorgio Chevallard30, Arturo Chieregato30, Giuseppe Citerio31, 32, Hans Clusmann33, Mark Coburn34, Jonathan Coles35, Jamie D. Cooper36, Marta Correia37, Amra Cović 38, Nicola Curry39, Endre Czeiter24, Marek Czosnyka26, Claire Dahyot Fizelier40, Paul Dark41, Helen Dawes42, Véronique De Keyser43, Vincent Degos16, Francesco Della Corte44, Hugo den Boogert10, Bart Depreitere45, Đula Đilvesi 46, Abhishek Dixit47, Emma Donoghue22, Jens Dreier48, Guy Loup Dulière49, Ari Ercole47, Patrick Esser42, Erzsébet Ezer50, Martin Fabricius51, Valery L. Feigin52, Kelly Foks53, Shirin Frisvold54, Alex Furmanov55, Pablo Gagliardo56, Damien Galanaud16, Dashiell Gantner28, Guoyi Gao57, Pradeep George58, Alexandre Ghuysen59, Lelde Giga60, Ben Glocker61, Jagoš Golubovic46, Pedro A. Gomez 62, Johannes Gratz63, Benjamin Gravesteijn64, Francesca Grossi44, Russell L. Gruen65, Deepak Gupta66, Juanita A. Haagsma64, Iain Haitsma67, Raimund Helbok13, Eirik Helseth68, Lindsay Horton 69, Jilske Huijben64, Peter J. Hutchinson70, Bram Jacobs71, Stefan Jankowski72, Mike Jarrett21, Ji yao Jiang58, Fave Johnson73, Kelly Jones52, Mladen Karan46, Angelos G. Kolias70, Erwin Kompanje74, Daniel Kondziella51, Evgenios Kornaropoulos47, Lars Owe Koskinen75, Noémi Kovács76, Ana Kowark77, Alfonso Lagares62, Linda Lanyon58, Steven Laureys78, Fiona Lecky79, 80, Didier Ledoux78, Rolf Lefering81, Valerie Legrand82, Aurelie Lejeune83, Leon Levi84, Roger Lightfoot85, Hester Lingsma64, Andrew I.R. Maas43, Ana M. Castaño León62, Marc Maegele86, Marek Majdan20, Alex Manara87, Geoffrey Manley88, Costanza Martino89, Hugues Maréchal49, Julia Mattern90, Catherine McMahon91, Béla Melegh92, David Menon47, Tomas Menovsky43, Ana Mikolic64, Benoit Misset78, Visakh Muraleedharan58, Lynnette Murray28, Ancuta Negru93, David Nelson1, Virginia Newcombe47, Daan Nieboer64, József

Nyirádi2, Otesile Olubukola79, Matej Oresic94, Fabrizio Ortolano27, Aarno Palotie95, 96, 97, Paul M. Parizel98, Jean François Payen99, Natascha Perera12, Vincent Perlbarg16, Paolo Persona100, Wilco Peull01, Anna Piippo-Karjalainen102, Matti Pirinen95, Dana Pisica64, Horia Ples93, Suzanne Polinder64, Inigo Pomposo29, Jussi P. Posti 103, Louis Puybasset104, Andreea Radoi 105, Arminas Ragauskas106, Rahul Raj102, Malinka Rambadagalla107, Isabel Retel Helmrich64, Jonathan Rhodes108, Sylvia Richardson109, Sophie Richter47, Samuli Ripatti95, Saulius Rocka106, Cecilie Roe110, Olav Roise111,112, Jonathan Rosand113, Jeffrey V. Rosenfeld114, Christina Rosenlund115, Guy Rosenthal55, Rolf Rossaint77, Sandra Rossi100, Daniel Rueckert61 Martin Rusnák116, Juan Sahuquillo105, Oliver Sakowitz90, 117, Renan Sanchez Porras117, Janos Sandor118, Nadine Schäfer81, Silke Schmidt119, Herbert Schoech120, Guus Schoonman121, Rico Frederik Schou122, Elisabeth Schwendenwein6, Charlie Sewalt64, Toril Skandsen123, 124, Peter Smielewski26, Abayomi Sorinola125, Emmanuel Stamatakis47, Simon Stanworth39, Robert Stevens126, William Stewart127, Ewout W. Steyerberg64, 128, Nino Stocchetti129, Nina Sundström130, Riikka Takala131, Viktória Tamás125, Tomas Tamosuitis132, Mark Steven Taylor20, Braden Te Ao52, Olli Tenovuo103, Alice Theadom52, Matt Thomas87, Dick Tibboel133, Marjolein Timmers74, Christos Tolias134, Tony Trapani28, Cristina Maria Tudora93, Andreas Unterberg90, Peter Vajkoczy 135, Shirley Vallance28, Egils Valeinis60, Zoltán Vámos50, Mathieu van der Jagt136, Gregory Van der Steen43, Joukje van der Naalt71, Jeroen T.J.M. van Dijck 101, Thomas A. van Essen101, Wim Van Hecke137, Caroline van Heugten138, Dominique Van Praag139, Ernest van Veen64, Thijs Vande Vyvere137, Roel P. J. van Wijk101, Alessia Vargiolu32, Emmanuel Vega83, Kimberley Velt64, Jan Verheyden137, Paul M. Vespa140, Anne Vik123, 141, Rimantas Vilcinis132, Victor Volovici67, Nicole von Steinbüchel38, Daphne Voormolen64, Petar Vulekovic46, Kevin K.W. Wang142, Eveline Wiegers64, Guy Williams47, Lindsay Wilson69, Stefan Winzeck47, Stefan Wolf143, Zhihui Yang113, Peter Ylén144, Alexander Younsi90, Frederick A. Zeiler47,145, Veronika Zelinkova20, Agate Ziverte60, Tommaso Zoerle27

1 Department of Physiology and Pharmacology, Section of Perioperative Medicine and Intensive Care, Karolinska Institutet, Stockholm, Sweden

2 János Szentágothai Research Centre, University of Pécs, Pécs, Hungary

3 Division of Surgery and Clinical Neuroscience, Department of Physical Medicine and Rehabilitation, Oslo University Hospital and University of Oslo, Oslo, Norway

4 Department of Neurosurgery, University Hospital Northern Norway, Tromso, Norway

5 Department of Physical Medicine and Rehabilitation, University Hospital Northern Norway,

Tromso, Norway

6 Trauma Surgery, Medical University Vienna, Vienna, Austria

7 Department of Anesthesiology & Intensive Care, University Hospital Nancy, Nancy, France

8 Raymond Poincare hospital, Assistance Publique - Hopitaux de Paris, Paris, France

9 Department of Anesthesiology & Intensive Care, S Raffaele University Hospital, Milan, Italy

10 Department of Neurosurgery, Radboud University Medical Center, Nijmegen, The Netherlands

11 Department of Neurosurgery, University of Szeged, Szeged, Hungary

12 International Projects Management, ARTTIC, Munchen, Germany

13 Department of Neurology, Neurological Intensive Care Unit, Medical University of Innsbruck, Innsbruck, Austria

14 Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska University Hospital, Stockholm, Sweden

15 NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK

16 Anesthesie-Réanimation, Assistance Publique - Hopitaux de Paris, Paris, France

17 Department of Anesthesia & ICU, AOU Città della Salute e della Scienza di Torino - Orthopedic and Trauma Center, Torino, Italy

18 Department of Neurology, Odense University Hospital, Odense, Denmark

19 BehaviourWorks Australia, Monash Sustainability Institute, Monash University, Victoria, Australia

20 Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University,

Trnava, Slovakia

21 Quesgen Systems Inc., Burlingame, California, USA

22 Australian & New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia

23 Department of Surgery and Perioperative Science, Umeå University, Umeå, Sweden

24 Department of Neurosurgery, Medical School, University of Pécs, Hungary and Neurotrauma Research Group, János Szentágothai Research Centre, University of Pécs, Hungary

25 Department of Medical Psychology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

26 Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK

27 Neuro ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy

28 ANZIC Research Centre, Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Victoria, Australia

29 Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain

30 NeuroIntensive Care, Niguarda Hospital, Milan, Italy

31 School of Medicine and Surgery, Università Milano Bicocca, Milano, Italy

32 NeuroIntensive Care, ASST di Monza, Monza, Italy

33Department of Neurosurgery, Medical Faculty RWTH Aachen University, Aachen, Germany

34 Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany

35 Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK

36 School of Public Health & PM, Monash University and The Alfred Hospital, Melbourne, Victoria, Australia

37 Radiology/MRI department, MRC Cognition and Brain Sciences Unit, Cambridge, UK

38 Institute of Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen, Göttingen,

Germany

39 Oxford University Hospitals NHS Trust, Oxford, UK

40 Intensive Care Unit, CHU Poitiers, Potiers, France

41 University of Manchester NIHR Biomedical Research Centre, Critical Care Directorate, Salford Royal Hospital NHS Foundation Trust, Salford, UK

42 Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University,

Oxford, UK

43 Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem,

Belgium

44 Department of Anesthesia & Intensive Care, Maggiore Della Carità Hospital, Novara, Italy

45 Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium

46 Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

47 Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK

48 Center for Stroke Research Berlin, Charité - Universitätsmedizin Berlin, corporate member of

Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin,

Germany

49 Intensive Care Unit, CHR Citadelle, Liège, Belgium

50 Department of Anaesthesiology and Intensive Therapy, University of Pécs, Pécs, Hungary

51 Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark

52 National Institute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Studies, Auckland University of Technology, Auckland, New Zealand

53 Department of Neurology, Erasmus MC, Rotterdam, the Netherlands

54 Department of Anesthesiology and Intensive care, University Hospital Northern Norway, Tromso, Norway

55 Department of Neurosurgery, Hadassah-hebrew University Medical center, Jerusalem, Israel

56 Fundación Instituto Valenciano de Neurorrehabilitación (FIVAN), Valencia, Spain

57 Department of Neurosurgery, Shanghai Renji hospital, Shanghai Jiaotong University/school of medicine, Shanghai, China

58 Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility, Stockholm, Sweden

- 59 Emergency Department, CHU, Liège, Belgium
- 60 Neurosurgery clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia

61 Department of Computing, Imperial College London, London, UK

62 Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain

63 Department of Anesthesia, Critical Care and Pain Medicine, Medical University of Vienna, Austria

64 Department of Public Health, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands

- 65 College of Health and Medicine, Australian National University, Canberra, Australia
- 66 Department of Neurosurgery, Neurosciences Centre & JPN Apex trauma centre, All India Institute
- of Medical Sciences, New Delhi-110029, India

67 Department of Neurosurgery, Erasmus MC, Rotterdam, the Netherlands

68 Department of Neurosurgery, Oslo University Hospital, Oslo, Norway

69 Division of Psychology, University of Stirling, Stirling, UK

70 Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital & University of Cambridge, Cambridge, UK

71 Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

72 Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

73 Salford Royal Hospital NHS Foundation Trust Acute Research Delivery Team, Salford, UK

74 Department of Intensive Care and Department of Ethics and Philosophy of Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

75 Department of Clinical Neuroscience, Neurosurgery, Umeå University, Umeå, Sweden

76 Hungarian Brain Research Program - Grant No. KTIA\_13\_NAP-A-II/8, University of Pécs, Pécs, Hungary

77 Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany

78 Cyclotron Research Center, University of Liège, Liège, Belgium

79 Centre for Urgent and Emergency Care Research (CURE), Health Services Research Section, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

- 80 Emergency Department, Salford Royal Hospital, Salford UK
- 81 Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University, Cologne,

Germany

82 VP Global Project Management CNS, ICON, Paris, France

83 Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France

84 Department of Neurosurgery, Rambam Medical Center, Haifa, Israel

85 Department of Anesthesiology & Intensive Care, University Hospitals Southhampton NHS Trust, Southhampton, UK

86 Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic Surgery

and Sportmedicine, Witten/Herdecke University, Cologne, Germany

87 Intensive Care Unit, Southmead Hospital, Bristol, Bristol, UK

88 Department of Neurological Surgery, University of California, San Francisco, California, USA

89 Department of Anesthesia & Intensive Care, M. Bufalini Hospital, Cesena, Italy

90 Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany

91 Department of Neurosurgery, The Walton centre NHS Foundation Trust, Liverpool, UK

92 Department of Medical Genetics, University of Pécs, Pécs, Hungary

93 Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara, Romania

94 School of Medical Sciences, Örebro University, Örebro, Sweden

95 Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

96 Analytic and Translational Genetics Unit, Department of Medicine; Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

97 Program in Medical and Population Genetics; The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA

98 Department of Radiology, University of Antwerp, Edegem, Belgium

99 Department of Anesthesiology & Intensive Care, University Hospital of Grenoble, Grenoble, France

100 Department of Anesthesia & Intensive Care, Azienda Ospedaliera Università di Padova, Padova, Italy

101 Dept. of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands and Dept. of

Neurosurgery, Medical Center Haaglanden, The Hague, The Netherlands

102 Department of Neurosurgery, Helsinki University Central Hospital

103 Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain Injury Centre,

Turku University Hospital and University of Turku, Turku, Finland

104 Department of Anesthesiology and Critical Care, Pitié -Salpêtrière Teaching Hospital, AssistancePublique, Hôpitaux de Paris and University Pierre et Marie Curie, Paris, France

105 Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron Research Institute, Barcelona, Spain

106 Department of Neurosurgery, Kaunas University of technology and Vilnius University, Vilnius, Lithuania

107 Department of Neurosurgery, Rezekne Hospital, Latvia

108 Department of Anaesthesia, Critical Care & Pain Medicine NHS Lothian & University of Edinburg, Edinburgh, UK

109 Director, MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK

110 Department of Physical Medicine and Rehabilitation, Oslo University Hospital/University of Oslo, Oslo, Norway

111 Division of Orthopedics, Oslo University Hospital, Oslo, Norway

112 Institue of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

113 Broad Institute, Cambridge MA Harvard Medical School, Boston MA, Massachusetts General Hospital, Boston MA, USA

114 National Trauma Research Institute, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia

115 Department of Neurosurgery, Odense University Hospital, Odense, Denmark

116 International Neurotrauma Research Organisation, Vienna, Austria

117 Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany

118 Division of Biostatistics and Epidemiology, Department of Preventive Medicine, University of

Debrecen, Debrecen, Hungary

119 Department Health and Prevention, University Greifswald, Greifswald, Germany

120 Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg, Austria

121 Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands

122 Department of Neuroanesthesia and Neurointensive Care, Odense University Hospital, Odense, Denmark

123 Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, NTNU, Trondheim, Norway

124 Department of Physical Medicine and Rehabilitation, St.Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

125 Department of Neurosurgery, University of Pécs, Pécs, Hungary

126 Division of Neuroscience Critical Care, John Hopkins University School of Medicine, Baltimore,

USA

127 Department of Neuropathology, Queen Elizabeth University Hospital and University of Glasgow, Glasgow, UK

128 Dept. of Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands

129 Department of Pathophysiology and Transplantation, Milan University, and Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy

130 Department of Radiation Sciences, Biomedical Engineering, Umeå University, Umeå, Sweden

131 Perioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital and University of Turku, Turku, Finland

132 Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania

133 Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands

134 Department of Neurosurgery, Kings college London, London, UK

135 Neurologie, Neurochirurgie und Psychiatrie, Charité – Universitätsmedizin Berlin, Berlin, Germany

136 Department of Intensive Care Adults, Erasmus MC- University Medical Center Rotterdam,

Rotterdam, the Netherlands

137 icoMetrix NV, Leuven, Belgium

138 Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University,

Oxford, UK

139 Psychology Department, Antwerp University Hospital, Edegem, Belgium

140 Director of Neurocritical Care, University of California, Los Angeles, USA

141 Department of Neurosurgery, St.Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

142 Department of Emergency Medicine, University of Florida, Gainesville, Florida, USA

143 Department of Neurosurgery, Charité – Universitätsmedizin Berlin, corporate member of Freie

Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

144 VTT Technical Research Centre, Tampere, Finland

145 Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

# REFERENCES

1. Maas AIR, Menon DK, Manley GT, Abrams M, Akerlund C, Andelic N, et al. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol. 2022;21(11):1004-60.

2. Roozenbeek B, Maas AIR, Menon DK. Changing patterns in the epidemiology of traumatic brain injury. Nature Reviews Neurology. 2013;9(4):231-6.

3. Gardner RC, Dams-O'Connor K, Morrissey MR, Manley GT. Geriatric traumatic brain injury: Epidemiology, outcomes, knowledge gaps, and future directions. Journal of Neurotrauma. 2018;35(7):889-906.

4. Karibe H, Hayashi T, Narisawa A, Kameyama M, Nakagawa A, Tominaga T. Clinical characteristics and outcome in elderly patients with traumatic brain injury: For establishment of management strategy. Neurologia Medico-Chirurgica. 2017;57(8):418-25.

5. Siman-Tov M, Radomislensky I, Knoller N, Bahouth H, Kessel B, Klein Y, et al. Incidence and injury characteristics of traumatic brain injury: Comparison between children, adults and seniors in Israel. Brain Injury. 2016;30(1):83-9.

6. McIntyre A, Mehta S, Aubut J, Dijkers M, Teasell RW. Mortality among older adults after a traumatic brain injury: A meta-analysis. Brain Injury. 2013;27(1):31-40.

7. Røe C, Skandsen T, Anke A, Ader T, Vik A, Lund SB, et al. Severe traumatic brain injury in norway: Impact of age on outcome. Journal of Rehabilitation Medicine. 2013;45(8):734-40.

8. Steyerberg EW, Mushkudiani N, Perel P, Butcher I, Lu J, McHugh GS, et al. Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics. PLoS Med. 2008;5(8):e165; discussion

e.

9. Collaborators MCT, Perel P, Arango M, Clayton T, Edwards P, Komolafe E, et al. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ. 2008;336(7641):425-9.

10. Isokuortti H, Iverson GL, Kataja A, Brander A, Öhman J, Luoto TM. Who gets head trauma or recruited in mild traumatic brain injury research? Journal of Neurotrauma. 2016;33(2):232-41.

11. Cnossen MC, Polinder S, Andriessen TM, van der Naalt J, Haitsma I, Horn J, et al. Causes and Consequences of Treatment Variation in Moderate and Severe Traumatic Brain Injury: A Multicenter Study. Critical care medicine. 2017;45(4):660-9.

12. Hurria A, Levit LA, Dale W, Mohile SG, Muss HB, Fehrenbacher L, et al. Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. J Clin Oncol. 2015;33(32):3826-33.

13. Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65(9):1226-9.

14. van Essen TA, den Boogert HF, Cnossen MC, de Ruiter GCW, Haitsma I, Polinder S, et al. Variation in neurosurgical management of traumatic brain injury: a survey in 68 centers participating in the CENTER-TBI study. Acta Neurochir (Wien). 2019;161(3):435-49.

15. Skaansar O, Tverdal C, Ronning PA, Skogen K, Brommeland T, Roise O, et al. Traumatic brain injury-the effects of patient age on treatment intensity and mortality. BMC Neurol. 2020;20(1):376.

16. Thompson HJ, Rivara FP, Jurkovich GJ, Wang J, Nathens AB, MacKenzie EJ. Evaluation of the effect of intensity of care on mortality after traumatic brain injury. Critical care medicine. 2008;36(1):282-90.

17. Maas AI, Menon DK, Steyerberg EW, Citerio G, Lecky F, Manley GT, et al. Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): a prospective longitudinal observational study. Neurosurgery. 2015;76(1):67-80.

18. Steyerberg EW, Wiegers E, Sewalt C, Buki A, Citerio G, De Keyser V, et al. Casemix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study. Lancet Neurol. 2019;18(10):923-34.

19. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998;15(8):573-85.

20. Heeringa S. Technical Description of the Health and Retirement Study Sample Design: Institute for Social Research, University of Michigan; 1995.

21. Kearney PM, Cronin H, O'Regan C, Kamiya Y, Savva GM, Whelan B, et al. Cohort profile: the Irish Longitudinal Study on Ageing. Int J Epidemiol. 2011;40(4):877-84.

22. (2018) RCT. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.

23. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. 2011. 2011;45(3):67.

24. van Essen TA, Dijkman MD, Cnossen MC, Moudrous W, Ardon H, Schoonman GG, et al. Comparative Effectiveness of Surgery for Traumatic Acute Subdural Hematoma in an Aging Population. J Neurotrauma. 2019;36(7):1184-91.

25. Shimoda K, Maeda T, Tado M, Yoshino A, Katayama Y, Bullock MR. Outcome and surgical management for geriatric traumatic brain injury: analysis of 888 cases registered in the Japan Neurotrauma Data Bank. World Neurosurg. 2014;82(6):1300-6.

26. Younsi A, Fischer J, Habel C, Riemann L, Scherer M, Unterberg A, et al. Mortality and functional outcome after surgical evacuation of traumatic acute subdural hematomas in octa- and nonagenarians. Eur J Trauma Emerg Surg. 2021;47(5):1499-510.

27. Galimberti S, Graziano F, Maas AIR, Isernia G, Lecky F, Jain S, et al. Effect of frailty on 6-month outcome after traumatic brain injury: a multicentre cohort study with external validation. Lancet Neurol. 2022;21(2):153-62.

28. Butler RN. Age-ism: another form of bigotry. Gerontologist. 1969;9(4):243-6.

29. Levy SR, Macdonald JL. Progress on Understanding Ageism. J Soc Issues. 2016;72(1):5-25.

30. Fraser S, Lagace M, Bongue B, Ndeye N, Guyot J, Bechard L, et al. Ageism and COVID-19: what does our society's response say about us? Age Ageing. 2020;49(5):692-5.

31. Chang ES, Kannoth S, Levy S, Wang SY, Lee JE, Levy BR. Global reach of ageism on older persons' health: A systematic review. Plos One. 2020;15(1):e0220857.

32. Kirkman MA, Jenks T, Bouamra O, Edwards A, Yates D, Wilson MH. Increased mortality associated with cerebral contusions following trauma in the elderly: Bad patients or bad management? Journal of Neurotrauma. 2013;30(16):1385-90.

33. Rapoport MJ, Feinstein A. Age and functioning after mild traumatic brain injury: The acute picture. Brain Injury. 2001;15(10):857-64.

34. Petridis AK, Dörner L, Doukas A, Eifrig S, Barth H, Mehdorn M. Acute subdural hematoma in the elderly; clinical and CT factors influencing the surgical treatment decision. Zentralblatt fur Neurochirurgie. 2009;70(2):73-8.

35. De Bonis P, Pompucci A, Mangiola A, Paternoster G, Festa R, Nucci CG, et al. Decompressive craniectomy for elderly patients with traumatic brain injury: It's probably not worth the while. Journal of Neurotrauma. 2011;28(10):2043-8.

36. Giovine Z, Campbell D, Whitmill M, Markert R, Saxe J. Do all elderly patients with mild traumatic brain injury require admission? Brain Inj. 2014;28:769-70.

37. van Veen E, van der Jagt M, Citerio G, Stocchetti N, Epker JL, Gommers D, et al. End-of-life practices in traumatic brain injury patients: Report of a questionnaire from the CENTER-TBI study. Journal of critical care. 2020;58:78-88.

38. van Veen E, van der Jagt M, Citerio G, Stocchetti N, Gommers D, Burdorf A, et al. Occurrence and timing of withdrawal of life-sustaining measures in traumatic brain injury patients: a CENTER-TBI study. Intensive Care Med. 2021;47(10):1115-29.

39. Feng J, van Veen E, Yang C, Huijben JA, Lingsma HF, Gao G, et al. Comparison of Care System and Treatment Approaches for Patients with Traumatic Brain Injury in China versus Europe: A CENTER-TBI Survey Study. J Neurotrauma. 2020;37(16):1806-17.

40. Kehoe A, Smith JE, Bouamra O, Edwards A, Yates D, Lecky F. Older patients with traumatic brain injury present with a higher GCS score than younger patients for a given severity of injury. Emerg Med J. 2016;33(6):381-5.

41. Lecky FE, Otesile O, Marincowitz C, Majdan M, Nieboer D, Lingsma HF, et al. The burden of traumatic brain injury from low-energy falls among patients from 18 countries in the CENTER-TBI Registry: A comparative cohort study. PLoS Med. 2021;18(9):e1003761.

42. Alali AS, Mukherjee K, McCredie VA, Golan E, Shah PS, Bardes JM, et al. Betablockers and Traumatic Brain Injury: A Systematic Review, Meta-analysis, and Eastern Association for the Surgery of Trauma Guideline. Ann Surg. 2017;266(6):952-61.

43. Bauer J, Harrison G, Grandhi R, Voronovich Z, Puccio A, Okonkwo DO. Pre-morbid and hospital course factors affecting intracranial hemorrhage expansion and mortality in the elderly post traumatic brain injury. J Neurotrauma. 2012;29:A44-A5. 44. Pieracci FM, Eachempati SR, Shou J, Hydo LJ, Barie S. Degree of anticoagulation, but not warfarin use itself, predicts adverse outcomes after traumatic brain injury in elderly trauma patients. Journal of Trauma. 2007;63(3):525-30.

45. Panczykowski DM, Okonkwo DO. Premorbid oral antithrombotic therapy and risk for reaccumulation, reoperation, and mortality in acute subdural hematomas: Clinical article. Journal of Neurosurgery. 2011;114(1):47-52.

46. Pieracci FM, Eachempati SR, Shou J, Hydo LJ, Barie PS. Use of long-term anticoagulation is associated with traumatic intracranial hemorrhage and subsequent mortality in elderly patients hospitalized after falls: Analysis of the new york state administrative database. Journal of Trauma. 2007;63(3):519-24.

47. Peck KA, Calvo RY, Schechter MS, Sise CB, Kahl JE, Shackford MC, et al. The impact of preinjury anticoagulants and prescription antiplatelet agents on outcomes in older patients with traumatic brain injury. Journal of Trauma and Acute Care Surgery. 2014;76(2):431-6.

48. Nishijima DK, Shahlaie K, Sarkar K, Rudisill N, Holmes JF. Risk of unfavorable long-term outcome in older adults with traumatic intracranial hemorrhage and anticoagulant or antiplatelet use. American Journal of Emergency Medicine. 2013;31(8):1244-7.

49. Grandhi R, Harrison G, Voronovich Z, Bauer J, Chen SH, Nicholas D, et al. Preinjury warfarin, but not antiplatelet medications, increases mortality in elderly traumatic brain injury patients. Journal of Trauma and Acute Care Surgery. 2015;78(3):614-21.

50. Mitra B, Cameron PA, Gabbe BJ, Rosenfeld JV, Kavar B. Management and hospital outcome of the severely head injured elderly patient. ANZ J Surg. 2008;78(7):588-92.

51. Brazinova A, Mauritz W, Leitgeb J, Wilbacher I, Majdan M, Janciak I, et al. Outcomes of patients with severe traumatic brain injury who have Glasgow Coma Scale scores of 3 or 4 and are over 65 years old. J Neurotrauma. 2010;27(9):1549-55.

52. Dams-O'Connor K, Gibbons LE, Landau A, Larson EB, Crane PK. Health Problems Precede Traumatic Brain Injury in Older Adults. Journal of the American Geriatrics Society. 2016;64(4):844-8.

53. Ikonomovic MD, Mi Z, Abrahamson EE. Disordered APP metabolism and neurovasculature in trauma and aging: Combined risks for chronic neurodegenerative disorders. Ageing Research Reviews. 2017;34:51-63.

54. Liu H, Yang Y, Xia Y, Zhu W, Leak RK, Wei Z, et al. Aging of cerebral white matter. Ageing Research Reviews. 2017;34:64-76.

55. Nedel WL, Silveira FD. Different research designs and their characteristics in intensive care. Rev Bras Ter Intensiva. 2016;28(3):256-60.

	All n = 4349	≤65 years old n = 3156	>65 years old n = 1193	p- value	Missing
Patient characteristics					
Age (median [IQR])	51.00 [32.00, 67.00]	42.00 [27.00, 54.00]	75.00 [70.00, 80.00]	< 0.001	0.0
Sex male (%)	2926 (67.3)	2226 (70.5)	700 (58.7)	< 0.001	0.0
Preinjury ASAPS classification (%)				< 0.001	3.1
A normal healthy patient	2352 (55.8)	2118 (69.3)	234 (20.2)		
A patient with a mild systemic disease	1401 (33.3)	771 (25.2)	630 (54.5)		
A patient with a severe systemic disease (that is a constant threat to life)**	460 (10.9)	167 (5.5)	293 (25.3)		
Use of anticoagulants or platelet inhibitors (%)	738 (17.6)	182 (6.0)	556 (49.0)	< 0.001	3.8
Use of betablockers (%)	435 (10.5)	125 (4.1)	310 (28.1)	< 0.001	4.8
ICU admission (%)	2055 (47.3)	1530 (48.5)	525 (44.0)	0.009	0.0
<b>Baseline characteristics</b>					
Injury cause (%)				< 0.001	2.8
Road traffic incident	1619 (38.3)	1355 (44.2)	264 (22.7)		
Incidental fall	1955 (46.2)	1148 (37.5)	807 (69.3)		
Other	654 (15.5)	560 (18.3)	94 (8.1)		
GCS motor baseline (%)				0.041	2.3
1	647 (15.2)	488 (15.8)	159 (13.6)		
2	77 (1.8)	54 (1.8)	23 (2.0)		
3	79 (1.9)	68 (2.2)	11 (0.9)		
4	151 (3.6)	109 (3.5)	42 (3.6)		
5	420 (9.9)	305 (9.9)	115 (9.9)		
6	2874 (67.7)	2057 (66.8)	817 (70.0)		
Pupils baseline (%)				0.412	5.9
Both reactive	3654 (89.3)	2667 (89.6)	987 (88.4)		
One reactive	162 (4.0)	117 (3.9)	45 (4.0)		
Both unreactive	277 (6.8)	192 (6.5)	85 (7.6)		
Major Extracranial Injury (%)	1533 (35.2)	1180 (37.4)	353 (29.6)	< 0.001	0.0
CT characteristics					
Marshall CT classification (%)				< 0.001	7.7
Ι	1545 (38.5)	1188 (40.9)	357 (32.3)		
П	1434 (35.7)	1053 (36.2)	381 (34.5)		
III	152 (3.8)	128 (4.4)	24 (2.2)		
IV	33 (0.8)	28 (1.0)	5 (0.5)		
V/VI***	849 (21.2)	511 (17.6)	338 (30.6)		
Epidural hematoma present on CT (%)	445 (10.2)	385 (12.2)	60 (5.0)	< 0.001	0.0
Acute subdural hematoma present on CT (%)	1173 (27.0)	751 (23.8)	422 (35.4)	< 0.001	0.0
Acute subarachnoid hemorrhage present on CT (%)	1858 (42.7)	1276 (40.4)	582 (48.8)	< 0.001	0.0

Midline shift present on CT (%)	476 (20.5)	euse allowed with 297 (9.4)	179 (15.0)	< 0.001	0.0
Surgical interventions					
Emergency intracranial surgery during hospital stay (%)	506 (11.7)	380 (12.2)	126 (10.6)	0.186	0.9
Emergency extracranial surgery during hospital stay (%)	337 (7.8)	286 (9.2)	51 (4.3)	< 0.001	0.9
Intracranial surgery during hospital stay (%)	859 (24.3)	642 (25.4)	217 (21.6)	0.020	18.7
Extracranial surgery during hospital stay (%)	714 (20.2)	587 (23.2)	127 (12.6)	< 0.001	18.7
Outcomes					
Length of hospital stay in days (median [IQR])	4.52 [0.99, 14.99]	4.49 [0.96, 15.74]	4.66 [1.05, 13.47]	0.965	2.6
IMPACT core probability of mortality (%)****	19 [12, 24]	15 [0.09, 0.19]	0.24 [0.24, 0.24]	< 0.001	6.6
IMPACT core probability of unfavorable outcome (%)****	40 [26, 47]	33 [21, 40]	47 [47, 47]	< 0.001	6.6
Glasgow Outcome Scale Extended (%)				< 0.001	15.8
Dead	470 (12.8)	200 (7.6)	270 (26.4)		
Vegetative state/lower severe disability	314 (8.6)	199 (7.5)	115 (11.2)		
Upper severe disability	174 (4.8)	120 (4.5)	54 (5.3)		
Lower moderate disability	339 (9.3)	295 (11.2)	44 (4.3)		
Upper moderate disability	383 (10.5)	333 (12.6)	50 (4.9)		
Lower good recovery	658 (18.0)	491 (18.6)	167 (16.3)		
Upper good recovery	1325 (36.2)	1002 (38.0)	323 (31.6)		

Abbreviations: ASAPS = American Society of Anesthesiologists Physical Status; CT = computed tomography; GCS = Glasgow coma scale; ICP = intracranial pressure; IMPACT = International Mission for Prognosis and Analysis of Clinical Trials in TBI; IQR = interquartile range; TBI = traumatic brain injury

\* P-values are a comparison between patients below versus over 65 years old.

\*\* Catergory 3 and 4 of the ASAPS classification were collapsed since category 4 had <50 patients.

\*\*\* Grading V and VI of the Marshall CT classification were collapsed since raters were not aware of (intent for) surgery and could thus not differentiate between grade V and VI

\*\*\*\* To calculate the probability of mortality and unfavorable outcome, we used the International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT) core model (8).

	All	≤65 years old	>65 years old	р-	M=
	n = 1999	n = 1486	n = 513	value*	Missing
Patient characteristics					
Age (median [IQR])	51.00 [31.00, 66.00]	41.00 [27.00, 54.00]	74.00 [69.00, 78.00]	< 0.001	0.0
Sex male (%)	1471 (73.6)	1132 (76.2)	339 (66.1)	< 0.001	0.0
Preinjury ASAPS classification (%)				< 0.001	4.4
A normal healthy patient	1081 (56.5)	977 (68.7)	104 (21.3)		
A patient with a mild systemic disease	625 (32.7)	356 (25.0)	269 (55.0)		
A patient with a severe systemic disease (that is a constant threat to life)**	206 (10.8)	90 (6.3)	116 (23.7)		
Use of anticoagulants or platelet inhibitors (%)	308 (16.3)	79 (5.6)	229 (48.5)	< 0.001	5.7
Use of betablockers (%)	192 (10.3)	62 (4.4)	130 (28.7)	< 0.001	7.1
Baseline characteristics					
Injury cause (%)				< 0.001	3.3
Road traffic incident	868 (44.9)	712 (49.7)	156 (31.3)		
Incidental fall	796 (41.2)	502 (35.0)	294 (58.9)		
Other	269 (13.9)	220 (15.3)	49 (9.8)		
GCS motor baseline (%)				0.020	2.0
1	622 (31.8)	474 (32.5)	148 (29.5)		
2	69 (3.5)	52 (3.6)	17 (3.4)		
3	76 (3.9)	68 (4.7)	8 (1.6)		
4	139 (7.1)	103 (7.1)	36 (7.2)		
5	361 (18.4)	265 (18.2)	96 (19.1)		
6	692 (35.3)	495 (34.0)	197 (39.2)		
Pupils baseline (%)				0.687	4.9
Both reactive	1533 (80.6)	1146 (81.0)	387 (79.3)		
One reactive	131 (6.9)	96 (6.8)	35 (7.2)		
Both unreactive	238 (12.5)	172 (12.2)	66 (13.5)		
Major Extracranial Injury (%)	1096 (54.8)	856 (57.6)	240 (46.8)	< 0.001	0.0
CT characteristics					
Marshall CT classification (%)				< 0.001	8.5
Ι	172 (9.4)	148 (10.8)	24 (5.2)		
II	787 (43.0)	637 (46.5)	150 (32.8)		
III	137 (7.5)	114 (8.3)	23 (5.0)		
IV	27 (1.5)	25 (1.8)	2 (0.4)		
V/VI***	706 (38.6)	447 (32.6)	259 (56.6)		
Epidural hematoma present on CT (%)	339 (17.0)	294 (19.8)	45 (8.8)	< 0.001	0.0
Acute subdural hematoma present on CT (%)	860 (43.0)	591 (39.8)	269 (52.4)	< 0.001	0.0
Acute subarachnoid hemorrhage present on CT (%)	1336 (66.8)	962 (64.7)	374 (72.9)	0.001	0.0

All rights Midline shift present on CT (%)	409 (20.5)	euse allowed with 275 (18.5)	134 (26.1)	< 0.001	0.0
Interventions					
Intubation	1536 (77.6)	1162 (79.0)	374 (73.5)	0.012	1.0
Mechanical ventilation	1424 (72.0)	1069 (72.7)	355 (69.9)	0.242	1.1
Oxygen administration	1428 (75.8)	1057 (75.7)	371 (75.9)	0.995	5.7
Tracheostomy	437 (22.0)	341 (23.1)	96 (18.8)	0.052	0.6
Surgical interventions					
Emergency intracranial surgery	476 (23.9)	357 (24.2)	119 (23.3)	0.737	0.5
during hospital stay (%) Emergency extracranial surgery	271 (13.6)	237 (16.0)	34 (6.7)	< 0.001	0.6
during hospital stay (%) Intracranial surgery during hospital stay (%)	777 (39.1)	586 (39.7)	191 (37.3)	0.360	0.6
Extracranial surgery during hospital stay (%)	577 (29.0)	487 (33.0)	90 (17.6)	< 0.001	0.6
ICP control					
ICP monitor during ICU stay (%)	886 (44.3)	705 (47.4)	181 (35.3)	< 0.001	0.0
Maximum ICP in mmHg before receiving HIT (median [IQR])	17.00 [12.00, 22.50]	17.00 [12.50, 22.50]	16.50 [12.00, 22.25]	0.306	60.5
Mean ICP in mmHg before receiving HIT (median [IQR])	13.60 [9.62, 17.50]	13.71 [9.73, 17.12]	13.20 [9.16, 18.48]	0.491	60.5
Median ICP in mmHg before receiving HIT (median [IQR])	11.62 [8.00, 16.00]	11.78 [8.00, 15.82]	11.12 [7.03, 16.00]	0.792	60.5
Metabolic suppression for ICP control (with high dose barbiturates or propofol) (%)	315 (15.8)	265 (17.8)	50 (9.7)	< 0.001	0.0
Neuromuscular blockade (paralysis) (%)	361 (18.1)	309 (20.8)	52 (10.1)	< 0.001	0.0
Intensive hypocapnia for ICP control [PaCO2 < 4.0 kPa (30 mmHg)] (%)	41 (2.1)	34 (2.3)	7 (1.4)	0.275	0.0
Hypothermia below 35°C (%)	90 (4.5)	61 (4.1)	29 (5.7)	0.182	0.0
Decompressive craniectomy	166 (8.3)	133 (9.0)	33 (6.4)	0.091	0.0
Outcomes					
Length of hospital stay in days (median [IQR])	14.75 [6.77, 29.33]	15.93 [7.61, 31.49]	11.62 [4.96, 23.47]	< 0.001	3.9
IMPACT core probability of mortality 80% or higher (%)****	24 [15, 41]	19 [12, 41]	24 [24, 62]	< 0.001	6.2
IMPACT core probability of unfavorable outcome 80% or higher (%)****	47 [33, 68]	40 [26, 68]	47 [47, 84]	< 0.001	6.2
Glasgow Outcome Scale Extended (%)				< 0.001	13.3
Dead	383 (22.1)	184 (14.4)	199 (43.7)		
Vegetative state/lower severe disability	269 (15.5)	182 (14.2)	87 (19.1)		
Upper severe disability	119 (6.9)	94 (7.3)	25 (5.5)		
Lower moderate disability	239 (13.8)	222 (17.4)	17 (3.7)		
Upper moderate disability	219 (12.6)	203 (15.9)	16 (3.5)		
Lower good recovery	235 (13.6)	178 (13.9)	57 (12.5)		
Upper good recovery	270 (15.6)	216 (16.9)	54 (11.9)		
		1	1	1	

medRxiv preprint doi: https://doi.org/10.1101/2024.06.25.24309449; this version posted June 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations: ASAPS = American Society of Americ

ICP = intracranial pressure; IMPACT = International Mission for Prognosis and Analysis of Clinical Trials in TBI; IQR = interquartile range;

TBI = traumatic brain injury

\* P-values are a comparison between patients below versus over 65 years old.

\*\* Catergory 3 and 4 of the ASAPS classification were collapsed since category 4 had <50 patients.

\*\*\* Grading V and VI of the Marshall CT classification were collapsed since raters were not aware of (intent for) surgery and could thus not

differentiate between grade V and VI

\*\*\*\* To calculate the probability of mortality and unfavorable outcome, we used the International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT) core model (8). If the calculated probability of mortality was >80%, we denominated it ' high probability of mortality'. Likewise, if the calculated probability of unfavorable outcome was >80%, we considered it 'high probability of unfavorable outcome'.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.25.24309449; this version posted June 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3. Effect of age on outcome and on the probability of receiving one or more high

intensity treatments			
	OR* per 10 years [CI] for	OR* per 10 years [CI] for	
	patients ≤65	patients ≥65	
Entire cohort			
GOSE	0.90 [0.84 - 0.91]	0.62 [0.54 - 0.70]	
Emergency intracranial surgery	0.98 [0.89 - 1.07]	0.43 [0.32 - 0.56]	
ICU admission	0.94 [0.87 - 1.01]	0.63 [0.52 - 0.78]	
ICU cohort			
GOSE	0.84 [0.80 - 0.91]	0.48 [0.33 - 0.52]	
Metabolic suppression	0.85 [0.76 - 0.93]	0.90 [0.63 - 1.38]	
Neuromuscular blockade	0.88 [0.80 - 0.96]	0.60 [0.41 - 0.90]	
Intensive hypocapnia	0.88 [0.66 - 1.08]	0.22 [0.06 - 0.86]	
Hypothermia below 35°C	1.13 [0.95 - 1.34]	1.27 [0.74 - 2.05]	
Decompressive craniectomy	0.99 [0.86 - 1.12]	0.43 [0.24 - 0.75]	
Intracranial surgery	1.05 [0.90 - 1.19]	0.51 [0.30 - 0.84]	

Abbreviations: CI = confidence interval; GOSE = Glasgow Outcome Scale Extended; OR = Odds Ratio; ICU = intensive care unit \*An OR <1 indicates a lower probability of having a good outcome or of receiving the particular high intensity treatment per 10 years. For example, the OR of being admitted to the ICU is 0.63 for a 75 year old compared to a 65 year old. The OR per year can be calculated by taking the 10<sup>th</sup> root  $(10\sqrt{x})$  of the displayed OR.

\*\*All models of the entire cohort are adjusted for age; gender; cause of injury (road traffic accident, fall, or other); American Society of Anesthesiologists Physical Status (ASAPS) classification; pre-injury use of anticoagulants or platelet inhibitors; pre-injury use of beta blockers; GCS motor score at baseline; pupillary reactivity at baseline; major extracranial injury (MEI); Marshall CT classification. \*\*\* All models of the entire cohort are adjusted for age; gender; cause of injury (road traffic accident, fall, or other); American Society of Anesthesiologists Physical Status (ASAPS) classification; pre-injury use of anticoagulants or platelet inhibitors; pre-injury use of beta blockers; GCS motor score at baseline; pupillary reactivity at baseline; major extracranial injury (MEI); Marshall CT classification; median ICP before receiving the first HIT on the ICU.

Table 4. Sensitivity analyses - Effect of age on outcome and on the probability of				
receiving one or more high intensity treatments				
	OR* per 10 years [CI] for	OR* per 10 years [CI] for		
	patients ≤50	patients ≥50		
Entire cohort**				
GOSE	0.88 [0.81 - 0.92]	0.81 [0.73 - 0.84]		
Emergency intracranial surgery	1.11 [0.98 - 1.28]	0.63 [0.53 - 0.71]		
ICU admission	0.99 [0.89 - 1.09]	0.75 [0.67 - 0.86]		
ICU cohort***				
GOSE	0.85 [0.80 - 0.95]	0.67 [0.58 - 0.73]		
Metabolic suppression	0.90 [0.77 - 1.01]	0.79 [0.66 - 0.97]		
Neuromuscular blockade	0.95 [0.83 - 1.07]	0.69 [0.57 - 0.83]		
Intensive hypocapnia	0.76 [0.51 - 1.02]	0.80 [0.50 - 1.32]		
Hypothermia below 35°C	1.10 [0.85 - 1.41]	1.22 [0.92 - 1.61]		
Decompressive craniectomy	1.07 [0.86 - 1.28]	0.70 [0.55 - 0.92]		
Intracranial surgery	1.04 [0.83 - 1.25]	0.85 [0.68 - 1.09]		

Abbreviations: CI = confidence interval; GOSE = Glasgow Outcome Scale Extended; OR = Odds Ratio; ICU = intensive care unit \*An OR <1 indicates a lower probability of having a good outcome or of receiving the particular high intensity treatment per 10 years. For example, the OR of being admitted to the ICU in the entire cohort is 0.75 for a 60 year old compared to a 50 year old. The OR per year can be calculated by taking the  $10^{\text{th}}$  root  $(10\sqrt{x})$  of the displayed OR.

\*\*All models of the entire cohort are adjusted for age; gender; cause of injury (road traffic accident, fall, or other); American Society of Anesthesiologists Physical Status (ASAPS) classification; pre-injury use of anticoagulants or platelet inhibitors; pre-injury use of beta blockers; GCS motor score at baseline; pupillary reactivity at baseline; major extracranial injury (MEI); Marshall CT classification. \*\*\* All models of the entire cohort are adjusted for age; gender; cause of injury (road traffic accident, fall, or other); American Society of

Anesthesiologists Physical Status (ASAPS) classification; pre-injury use of anticoagulants or platelet inhibitors; pre-injury use of beta blockers; GCS motor score at baseline; pupillary reactivity at baseline; major extracranial injury (MEI); Marshall CT classification; median ICP before receiving the first HIT on the ICU.


# Table 5. Sensitivity analyses - Effect of age on outcome and on the probability of

receiving one or more high intensity treatments				
	OR* per 10 years [CI] for	OR* per 10 years [CI] for		
	patients ≤80	patients ≥80		
Entire cohort**				
GOSE	0.87 [0.81 - 0.88]	0.22 [0.18 - 0.43]		
Emergency intracranial surgery	0.88 [0.81 - 0.94]	0.21 [0.06 - 0.58]		
ICU admission	0.91 [0.85 - 0.97]	0.17 [0.08 - 0.37]		
ICU cohort***				
GOSE	0.79 [0.75 - 0.84]	0.11 [0.08 - 0.15]		
Metabolic suppression	0.86 [0.79 - 0.93]	0.44 [0.02 - 2.82]		
Neuromuscular blockade	0.84 [0.78 - 0.92]	0.37 [0.03 - 1.93]		
Intensive hypocapnia	0.78 [0.63 - 0.97]	0.00 [0.00 - Inf]		
Hypothermia below 35°C	1.17 [1.00 - 1.34]	0.67 [0.03 - 4.01]		
Decompressive craniectomy	0.89 [0.79 - 0.998]	0.85 [0.06 - 5.95]		
Intracranial surgery	0.98 [0.86 - 1.09]	0.00 [0.00 - 0.27]		


Abbreviations: CI = confidence interval; GOSE = Glasgow Outcome Scale Extended; OR = Odds Ratio; ICU = intensive care unit \*An OR <1 indicates a lower probability of having a good outcome or of receiving the particular high intensity treatment per 10 years. For example, the OR of being admitted to the ICU is 0.17 for a 90 year old compared to a 80 year old. The OR per year can be calculated by taking the  $10^{\text{th}}$  root ( $10\sqrt{x}$ ) of the displayed OR.

\*\*All models of the entire cohort are adjusted for age; gender; cause of injury (road traffic accident, fall, or other); American Society of Anesthesiologists Physical Status (ASAPS) classification; pre-injury use of anticoagulants or platelet inhibitors; pre-injury use of beta blockers; GCS motor score at baseline; pupillary reactivity at baseline; major extracranial injury (MEI); Marshall CT classification.
\*\*\* All models of the entire cohort are adjusted for age; gender; cause of injury (road traffic accident, fall, or other); American Society of Anesthesiologists Physical Status (ASAPS) classification; pre-injury use of anticoagulants or platelet inhibitors; pre-injury use of beta blockers; GCS motor score at baseline; pupillary reactivity at baseline; major extracranial injury (MEI); Marshall CT classification; median blockers; GCS motor score at baseline; pupillary reactivity at baseline; major extracranial injury (MEI); Marshall CT classification; median ICP before receiving the first HIT on the ICU.


# Predicted probability of unfavourable outcome per year\*




# Predicted probability of ICU admission per year\*





# Predicted probability of emergency intracranial surgery per year\*




# Predicted probability of unfavourable outcome per year\*









# Predicted probability of neuromuscular blockage per year\*




# Predicted probability of hypothermia below 35 degrees per year\*




# Predicted probability of unfavourable outcome per year\*



# Predicted probability of intensive hyperventilation per year\*



# Predicted probability of decompressive craniectomy per year\*



# Predicted probability of intracranial surgery per year\*

